Navigation Links
Prometheus Highlights Record Performance in 2010
Date:3/1/2011

e market-leading PROMETHEUS® IBD Serology 7. The Crohn's Prognostic test combines six serologic markers and three genetic mutation markers to provide physicians with a personalized serogenetic profile for their patients.  This test helps enable physicians to quantify these patients' risk of developing disease complications and is designed to provide information to assist physicians in determining optimal treatment strategies for their Crohn's patients.
  • In December, Prometheus extended its distribution agreement with AstraZeneca LP for the exclusive marketing, sales and distribution of ENTOCORT® EC (budesonide) Capsules in the United States the earlier of December 31, 2011 or 30 days after the sale of a generic equivalent in the United States.  Entocort EC is the only FDA-approved drug for the induction and maintenance of clinical remission in mild to moderate Crohn's disease involving the ileum and/or the ascending colon.  Entocort EC is indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon (up to 8 weeks with repeated 8-week courses as necessary for recurring episodes of active disease), and the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months.  Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 150.

  • Development Product Highlights

  • In March, Prometheus executed a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic CEER™ platform with certain compounds in Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products. Prometheus receiv
    '/>"/>

  • SOURCE Prometheus Laboratories Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
    2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
    3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
    4. Prometheus Launches ProOnc Dx Cancer Diagnostics
    5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
    6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
    7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
    8. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    9. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
    10. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... PLYMOUTH MEETING, Pa. , Sept. 22, 2014 ... ) announced today it has initiated a phase ... The trial will evaluate the safety, tolerability, and ... type 6 (HPV-6), which causes most aerodigestive cancers. ... tongue, nose, throat, vocal cords, and parts of ...
    (Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
    (Date:9/22/2014)... Pa. , Sept. 22, 2014 ... a specialty biopharmaceutical company, today announced that its ... unsolicited, non-binding and conditional proposal from Endo International ... financial and legal advisors, has unanimously determined it ... of its existing merger agreement with QLT Inc. ...
    Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
    ... SAN DIEGO, Feb. 6, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... quarter and year ended December 31, 2011. ... $164.9 million, which included net product sales of $160.9 million. ... 2011 was $17.6 million, compared to a non-GAAP operating income ...
    ... Feb. 6, 2012  Genomic Health, Inc. (Nasdaq: GHDX ... with the goal of improving the quality of diagnosis, communication ... with common and rare genetic conditions.   The subsidiary is expected ... first commercial service in 2013.  The new venture will be ...
    Cached Medicine Technology:Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 2Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 3Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 4Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 5Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 6Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 7Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 8Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 9Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
    (Date:9/22/2014)... new study pulls back the curtain on one of ... payment and income between physicians who perform operations, procedures ... to perception, the research indicates, the physician payment system ... procedure-performing doctors. , The new findings counter the widely ... minute explains why doctors who perform procedures often earn ...
    (Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... care units (NICU) set up private rooms for parents to ... Researchers at one children,s hospital found that preemies gained weight ... NICU switched from the traditional "open-bay" layout to private rooms ... the journal Pediatrics , add to evidence that private ...
    (Date:9/22/2014)... Up to 40 percent of patients undergoing breast cancer ... remove all the cancerous tissue in the initial operation. ... successfully tested a tool they developed that will help ... thereby decreasing the chances for repeat operations. ... of September 22, 2014 in the Proceedings of ...
    (Date:9/22/2014)... ON (September 22, 2014) McMaster scientists have found ... new class of antibiotics. , Although dozens of ... at how a certain part of bacteria are created, ... it. , The discovery is important as there ... making the cures for infections ineffective. The World Health ...
    (Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
    Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
    ... MONDAY, Jan. 16 (HealthDay News) -- Persistent pain, eating problems ... survivors of head and neck cancer, a new study finds. ... issue of the journal Archives of Otolaryngology -- Head ... were diagnosed with head and neck cancer from 1995 to ...
    ... ten Canadians cannot afford to take their prescription drugs as ... of British Columbia and the University of Toronto. ... Canadian Medical Association Journal ) is the first to examine ... drugs in Canada. Researchers from UBC,s Centre for Health Services ...
    ... most severe cases of Lupus (systemic lupus erythemathosus), an ... the activity of some critical genes of the immune ... Italian researchers at the Catholic University of Sacred Heart ... the accelerator of the car and boosts the pathological ...
    ... British Columbia have found a new way to block infection ... could lead to new therapies for those affected by this ... worldwide suffer from hepatitis C, the disease caused by chronic ... of the leading causes of liver cancer and liver transplant ...
    ... Scientists working at the Medical Research Council have identified ... pre-cancerous cells in the esophagus, a condition called Barrett,s ... these cells before they develop into esophageal cancer. These ... have important implications for patients and may help to ...
    ... -- Soccer players need to use the correct techniques ... redirect the ball -- to prevent possible brain injury, researchers ... between the sport and brain damage, Dr. Alejandro Spiotta and ... moving at high speeds when they come into contact with ...
    Cached Medicine News:Health News:Many Head and Neck Cancer Survivors Face Eating Problems 2Health News:1 in 10 Canadians cannot afford prescription drugs: UBC study 2Health News:A genetic accelerator hits the gas on autoimmune diseases 2Health News:UBC researchers identify potential new therapy approach for hepatitis C 2Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:Heading Soccer Balls Could Injure Brain 2
    ... with a curvature of 12 ... of the retina. Instrument shaft ... For cutting membranes adherent to ... for cutting in small folds ...
    Claes Shielded Retinotomy Scissors, Curved Vertical...
    Claes Shielded Retinotomy Scissors, Vertical...
    Indirect hemagglutination assay (IHA) for the detection and semi-quantitation of human antibodies to the bacteria of the genus Leptospira. Each kit contains test cells, control cells, and positive an...
    Medicine Products: